GlassScriptPhysician profile
Briana A Davis
NPI 1174275077
$1,918.78
in general payments reported to CMS, 2019-2025
15 companies · $639 in 2025
The $639 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $235 · 2023: $371 · 2024: $674 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,683.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $334.14 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $325.76 | 2022-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $306.56 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $286.82 | 2023-2024 | Jornay Pm |
| Tris Pharma INC | $160.59 | 2022-2024 | Dyanavel Xr, Quillivant, Quillichew Er |
| Axsome Therapeutics, INC. | $133.19 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $128.68 | 2022 | |
| Janssen Pharmaceuticals, INC | $64.05 | 2022 | |
| Vertical Pharmaceuticals, LLC | $44.52 | 2024-2025 | Relexxii |
| Dexcom, INC. | $37.39 | 2023 | Dexcom G6 Transmitter |
| Tolmar, INC. | $22.36 | 2025 | Fensolvi |
| Abbvie INC. | $22.22 | 2023 | |
| Xeris Pharmaceuticals, INC. | $21.37 | 2023 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $17.64 | 2024 | Shingrix, Arexvy |
| Pari Respiratory Equipment, INC. | $13.49 | 2023 | Kitabis Pak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Briana Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.